References
- Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011;17(3 Suppl):S1-S9
- Fink MA, Angus PW, Gow PJ, et al. Liver transplant recipient selection: MELD vs. clinical judgment. Liver Transpl 2005;11:621-6
- Akkina SK, Asrani SK, Peng Y, et al. Development of organ-specific donor risk indices. Liver Transpl. 2012;18:395-404
- European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8
- The US Multicentre FK506 Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-15
- Otto MG, Mayer AD, Clavien PA, et al. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Transplantation 1998;66:1632-40
- Loinaz C, Marin LM, González-Pinto I, et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. Transplant Proc 2001;33:3439-41
- Trunečka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010;10:2313-23
- Adam R, Karam V, Delvart V, et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 2015;15:1267-82
- Muduma G, Pollock RF, Odeyemi I, et al. Bayesian hierarchical modeling of randomized and nonrandomized studies comparing ciclosporin with immediate- and prolonged-release tacrolimus in liver transplant recipients. Value Health 2015;18:A222
- NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2013/14. Watford, UK. 2014. https://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2013_14.pdf. Accessed March 2, 2015
- O’Grady JG, Hardy P, Burroughs AK, et al.; UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007;7:137-41
- Marudanayagam R, Shanmugam V, Sandhu B, et al. Liver retransplantation in adults: a single-centre, 25-year experience. HPB (Oxford) 2010;12:217-24
- Schlitt HJ, Jonas S, Ganten TM. Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER). Clin Transplant 2013;27:368-78
- European Medicines Agency. Basiliximab European Public Assessment Report Scientific Discussion. London, UK. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000207/WC500053538.pdf. Accessed May 3, 2016
- Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006;12:1464-72
- Weigand K, Schnitzler P, Schmidt J, et al. Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis. Transplant Proc 2010;42:2634-41
- British Transplantation Society. Guidelines for the prevention and management of CMV disease after solid organ transplantation. 2011. 3rd edn. Macclesfield, UK. https://www.bts.org.uk/Documents/Guidelines/Active/Final%20CMV%20Guideline%20for%20web%2012-9-2011.pdf. Accessed May 3, 2016
- Azoulay D, Linhares MM, Huguet E, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-21
- Muduma G, Shaw J, Hart WM, et al. Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Prefer Adherence 2014;8:1537-46
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. London, UK. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf. Accessed March 2, 2015
- Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-70
- Aberg F, Rissanen AM, Sintonen H, et al. Health-related quality of life and employment status of liver transplant patients. Liver Transpl 2009;15:64-72
- National Institute for Health and Care Excellence. Kidney transplantation (adults) - immunosuppressive therapy (review of TA 85) [ID456]. London, UK. 2015. https://www.nice.org.uk/guidance/GID-TAG348/documents/kidney-transplantation-adults-immunosuppressive-therapy-review-of-ta-85-committee-papers-part-12. Accessed May 5, 2016
- Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9:1-179
- Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57:675-88
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-35
- Biggins SW, Beldecos A, Rabkin JM, et al. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-22